Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 3 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Assia Chemical Industries Ltd. is currently managing 8 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct art units, indicating that the company's patent applications cover several different specialized fields. The company is dealing with 8 distinct examiners, meaning that every single pending action is being reviewed by a different official.
The busiest examiner for the company is HERNANDEZ, JACKSON J, who is responsible for 1 busiest examiner pending action. Because the 8 pending office actions are distributed among different examiners, no single official has a dominant influence over the portfolio's current progress. This lack of concentration requires the company to adapt its prosecution strategy to the individual styles of many people. Furthermore, the 3 distinct art units involved mean that the company must also navigate the specific procedural nuances of different administrative groups within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (38%) |
| Multi-statute (no §101) | 5 (62%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
| SHOWALTER, ALEXANDER KEITH | 1 | 54.4% | +26.3% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| GONZALEZ, LUISALBERTO | 1 | 59.4% | +47.2% |
| PAGANO, ALEXANDER R | 1 | 78.7% | +11.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17798393 | SOLID STATE FORMS OF AVASOPASEM MANGANESE AND PROCESS FOR PREPARATION THEREOF | PAGANO, ALEXANDER R | 30d overdue |
| 18038506 | PROCESSES FOR THE PREPARATION OF ZANUBRUTINIB AND INTERMEDIATES THEREOF | GONZALEZ, LUISALBERTO | 4d overdue |
| 18843819 | SOLID STATE FORMS OF TOLEBRUTINIB AND OF TOLEBRUTINIB SALTS | HERNANDEZ, JACKSON J | — |
| 18710701 | SOLID STATE FORM OF TAFAMIDIS | NOTTINGHAM, KYLE GREGORY | — |
| 18710688 | SOLID STATE FORMS OF LOTILANER AND PROCESS FOR PREPARATION THEREOF | WELLS, LAUREN QUINLAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17798393 | SOLID STATE FORMS OF AVASOPASEM MANGANESE AND PROCESS FOR PREPARATION THEREOF | PAGANO, ALEXANDER R | 30d overdue |
| 18038506 | PROCESSES FOR THE PREPARATION OF ZANUBRUTINIB AND INTERMEDIATES THEREOF | GONZALEZ, LUISALBERTO | 4d overdue |
| 18843819 | SOLID STATE FORMS OF TOLEBRUTINIB AND OF TOLEBRUTINIB SALTS | HERNANDEZ, JACKSON J | — |
| 18837960 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | SHOWALTER, ALEXANDER KEITH | — |
| 18710701 | SOLID STATE FORM OF TAFAMIDIS | NOTTINGHAM, KYLE GREGORY | — |
| 18710688 | SOLID STATE FORMS OF LOTILANER AND PROCESS FOR PREPARATION THEREOF | WELLS, LAUREN QUINLAN | — |
| 18567414 | SOLID STATE FORMS OF 4-[[4-(4-CHLOROANILINO)FURO[2,3-d]PYRIDAZIN-7-yl]OXYMETHYL]-N-METHYLPYRIDINE-2-CARBOXAMIDE AND SALT THEREOF | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1624 | 1 |
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843819 | SOLID STATE FORMS OF TOLEBRUTINIB AND OF TOLEBRUTINIB SALTS | HERNANDEZ, JACKSON J | — | §103§112 | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18837960 | CRYSTALLINE FORMS OF TRILACICLIB AND TRILACICLIB SALTS | SHOWALTER, ALEXANDER KEITH | — | §112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18727806 | SOLID STATE FORMS OF RUCAPARIB TOSYLATE | SHTERENGARTS, SAMANTHA L | — | §112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18710701 | SOLID STATE FORM OF TAFAMIDIS | NOTTINGHAM, KYLE GREGORY | — | §102§103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18710688 | SOLID STATE FORMS OF LOTILANER AND PROCESS FOR PREPARATION THEREOF | WELLS, LAUREN QUINLAN | — | §103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18567414 | SOLID STATE FORMS OF 4-[[4-(4-CHLOROANILINO)FURO[2,3-d]PYRIDAZIN-7-yl]OXYMETHYL]-N-METHYLPYRIDINE-2-CARBOXAMIDE AND SALT THEREOF | RODRIGUEZ, RAYNA B | 1628 | §112 | Final Rejection | — | Pending | Dec 06, 2023 |
| 18038506 | PROCESSES FOR THE PREPARATION OF ZANUBRUTINIB AND INTERMEDIATES THEREOF | GONZALEZ, LUISALBERTO | 1624 | §102§103 | Final Rejection | 4d overdue | Pending | May 24, 2023 |
| 17798393 | SOLID STATE FORMS OF AVASOPASEM MANGANESE AND PROCESS FOR PREPARATION THEREOF | PAGANO, ALEXANDER R | 1692 | §102§103§112 | Non-Final OA | 30d overdue | Pending | Aug 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial